SCHEMBL23744698

SCHEMBL23744698

C[C@@H]1CN(c2ccccc2C(F)(F)F)C[C@H](C)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 4/20 0.44
KMT2A Q03164 2/20 0.44
HSD11B1 P28845 3/20 0.44
AKR1C3 P42330 1/20 0.41
HTR2C P28335 3/20 0.40
TTR P02766 1/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
PMP22 Q01453 1/20 0.39
DRD4 P21917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345707 1.00 RBP4 (0.44) RBP4KMT2AHSD11B1AKR1C3HTR2C
SCHEMBL30345809 1.00 RBP4 (0.44) RBP4KMT2AHSD11B1AKR1C3HTR2C
SCHEMBL23744701 1.00 RBP4 (0.44) RBP4KMT2AHSD11B1AKR1C3HTR2C
SCHEMBL30345613 0.82 HTR2C (0.59) RBP4KMT2AHSD11B1AKR1C3HTR2C
SCHEMBL3219375 0.82 HTR2C (0.59) RBP4KMT2AHSD11B1AKR1C3HTR2C
SCHEMBL23744700 0.82 HTR2C (0.59) RBP4KMT2AHSD11B1AKR1C3HTR2C
SCHEMBL3219365 0.82 HTR2C (0.59) RBP4KMT2AHSD11B1AKR1C3HTR2C
SCHEMBL19614564 0.80 NOTUM (0.48) RBP4KMT2AHSD11B1AKR1C3TTR
SCHEMBL22765834 0.79 HSD11B1 (0.46) RBP4KMT2AHSD11B1AKR1C3TTR
SCHEMBL24123780 0.79 HTR2C (0.40) RBP4HTR2CHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 RBP4 2305/4885KMT2A 1920/4885HSD11B1 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.